ONCOLOGY Staff

“You have to be on your game continually, you have to continually self-evaluate, and the field moves quickly.”

Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.

Experts from leading institutions debate the latest advances in multiple myeloma.

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.

Centering discussion on clinical scenarios of urothelial carcinoma, expert oncologists review recent data and discuss how patient care is evolving.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).

Martin Dietrich, MD, PhD, Sara Tolaney, MD, MPH, and Gregory Vidal, MD, PhD review recent data from the TROPiCS-02 trial on sacituzumab govitecan and discuss the clinical implications of these findings.

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

Expert oncologists review clinical scenarios to define best treatment practices for patients with EGFR-mutated non–small cell lung cancer.

Centering discussion on two clinical scenarios, expert panelists review recent evolutions in the field of graft-vs-host disease management and provide their perspective on optimal treatment strategies.

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

“Opportunities to escalate therapies that work well in stage IV into what we consider a more curative setting...are exactly what we need to be looking for.” –Mark A. Socinski, MD

A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

A panel of experts in breast oncology builds a lively discussion on evolving approaches in the management of HER2+ metastatic breast cancer, including key considerations for the treatment of patients with brain metastases.

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

A panel of oncologists reviews a publication by Robert J. Motzer, MD, and colleagues on data from the CLEAR trial examining lenvatinib plus either pembrolizumab or everolimus for advanced renal cell carcinoma.

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

Stacy A. Cohen, MD, and Mark Lewis, MD, review results from the GALAXY study on circulating tumor DNA dynamics in CRC.

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.

A panel of experts review two patient cases to elucidate data in the adjuvant setting of non–small cell lung cancer.

Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.